Selected research
Industry Research
Psychoactive Substances Industry Research Report 2026
Market perspective
The global Psychoactive Substances market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Psychoactive Substances market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Psychoactive Substances market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Psychoactive Substances market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Psychoactive Substances include Alpha-CAT, AusCann Group Holdings Pty Ltd., Cannabics Pharmaceuticals Inc., Cape Bouvard Technologies Pty Ltd, Cyrelian Pty Ltd., Enecta., GD Pharma, GW Pharmaceuticals PLC. and MedReleaf Australia, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Psychoactive Substances market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Psychoactive Substances.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Psychoactive Substances Market by Company
Alpha-CAT
AusCann Group Holdings Pty Ltd.
Cannabics Pharmaceuticals Inc.
Cape Bouvard Technologies Pty Ltd
Cyrelian Pty Ltd.
Enecta.
GD Pharma
GW Pharmaceuticals PLC.
MedReleaf Australia
Teewinot Life Sciences
Tilray
Zynerba Pharmaceuticals
Psychoactive Substances Segment by Type
Cannabinoids
Hallucinogens
Stimulants
Depressants
Psychoactive Substances Segment by Application
Neuropathic Disorders
Spasticity
Cancer
Psychoactive Substances Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psychoactive Substances market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Psychoactive Substances and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psychoactive Substances.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Psychoactive Substances companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cannabinoids
- Hallucinogens
- Stimulants
- Depressants
Applications
- Neuropathic Disorders
- Spasticity
- Cancer
Companies covered
- Alpha-CAT
- AusCann Group Holdings Pty Ltd.
- Cannabics Pharmaceuticals Inc.
- Cape Bouvard Technologies Pty Ltd
- Cyrelian Pty Ltd.
- Enecta.
- GD Pharma
- GW Pharmaceuticals PLC.
- MedReleaf Australia
- Teewinot Life Sciences
- Tilray
- Zynerba Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Psychoactive Substances by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Cannabinoids
- 2.2.3 Hallucinogens
- 2.2.4 Stimulants
- 2.2.5 Depressants
- 2.3 Psychoactive Substances by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Neuropathic Disorders
- 2.3.3 Spasticity
- 2.3.4 Cancer
- 2.4 Assumptions and Limitations
3 Psychoactive Substances Breakdown Data by Type
- 3.1 Global Psychoactive Substances Historic Market Size by Type (2021-2026)
- 3.2 Global Psychoactive Substances Forecasted Market Size by Type (2027-2032)
4 Psychoactive Substances Breakdown Data by Application
- 4.1 Global Psychoactive Substances Historic Market Size by Application (2021-2026)
- 4.2 Global Psychoactive Substances Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Psychoactive Substances Market Perspective (2021-2032)
- 5.2 Global Psychoactive Substances Growth Trends by Region
- 5.2.1 Global Psychoactive Substances Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Psychoactive Substances Historic Market Size by Region (2021-2026)
- 5.2.3 Psychoactive Substances Forecasted Market Size by Region (2027-2032)
- 5.3 Psychoactive Substances Market Dynamics
- 5.3.1 Psychoactive Substances Industry Trends
- 5.3.2 Psychoactive Substances Market Drivers
- 5.3.3 Psychoactive Substances Market Challenges
- 5.3.4 Psychoactive Substances Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Psychoactive Substances Players by Revenue
- 6.1.1 Global Top Psychoactive Substances Players by Revenue (2021-2026)
- 6.1.2 Global Psychoactive Substances Revenue Market Share by Players (2021-2026)
- 6.2 Global Psychoactive Substances Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Psychoactive Substances Head Office and Area Served
- 6.4 Global Psychoactive Substances Players, Product Type & Application
- 6.5 Global Psychoactive Substances Manufacturers Established Date
- 6.6 Global Psychoactive Substances Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Psychoactive Substances Market Size (2021-2032)
- 7.2 North America Psychoactive Substances Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Psychoactive Substances Market Size by Country (2021-2026)
- 7.4 North America Psychoactive Substances Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Psychoactive Substances Market Size (2021-2032)
- 8.2 Europe Psychoactive Substances Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Psychoactive Substances Market Size by Country (2021-2026)
- 8.4 Europe Psychoactive Substances Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Psychoactive Substances Market Size (2021-2032)
- 9.2 Asia-Pacific Psychoactive Substances Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Psychoactive Substances Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Psychoactive Substances Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Psychoactive Substances Market Size (2021-2032)
- 10.2 South America Psychoactive Substances Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Psychoactive Substances Market Size by Country (2021-2026)
- 10.4 South America Psychoactive Substances Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Psychoactive Substances Market Size (2021-2032)
- 11.2 Middle East & Africa Psychoactive Substances Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Psychoactive Substances Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Psychoactive Substances Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Alpha-CAT
- 12.1.1 Alpha-CAT Company Information
- 12.1.2 Alpha-CAT Business Overview
- 12.1.3 Alpha-CAT Revenue in Psychoactive Substances Business (2021-2026)
- 12.1.4 Alpha-CAT Psychoactive Substances Product Portfolio
- 12.1.5 Alpha-CAT Recent Developments
- 12.2 AusCann Group Holdings Pty Ltd.
- 12.2.1 AusCann Group Holdings Pty Ltd. Company Information
- 12.2.2 AusCann Group Holdings Pty Ltd. Business Overview
- 12.2.3 AusCann Group Holdings Pty Ltd. Revenue in Psychoactive Substances Business (2021-2026)
- 12.2.4 AusCann Group Holdings Pty Ltd. Psychoactive Substances Product Portfolio
- 12.2.5 AusCann Group Holdings Pty Ltd. Recent Developments
- 12.3 Cannabics Pharmaceuticals Inc.
- 12.3.1 Cannabics Pharmaceuticals Inc. Company Information
- 12.3.2 Cannabics Pharmaceuticals Inc. Business Overview
- 12.3.3 Cannabics Pharmaceuticals Inc. Revenue in Psychoactive Substances Business (2021-2026)
- 12.3.4 Cannabics Pharmaceuticals Inc. Psychoactive Substances Product Portfolio
- 12.3.5 Cannabics Pharmaceuticals Inc. Recent Developments
- 12.4 Cape Bouvard Technologies Pty Ltd
- 12.4.1 Cape Bouvard Technologies Pty Ltd Company Information
- 12.4.2 Cape Bouvard Technologies Pty Ltd Business Overview
- 12.4.3 Cape Bouvard Technologies Pty Ltd Revenue in Psychoactive Substances Business (2021-2026)
- 12.4.4 Cape Bouvard Technologies Pty Ltd Psychoactive Substances Product Portfolio
- 12.4.5 Cape Bouvard Technologies Pty Ltd Recent Developments
- 12.5 Cyrelian Pty Ltd.
- 12.5.1 Cyrelian Pty Ltd. Company Information
- 12.5.2 Cyrelian Pty Ltd. Business Overview
- 12.5.3 Cyrelian Pty Ltd. Revenue in Psychoactive Substances Business (2021-2026)
- 12.5.4 Cyrelian Pty Ltd. Psychoactive Substances Product Portfolio
- 12.5.5 Cyrelian Pty Ltd. Recent Developments
- 12.6 Enecta.
- 12.6.1 Enecta. Company Information
- 12.6.2 Enecta. Business Overview
- 12.6.3 Enecta. Revenue in Psychoactive Substances Business (2021-2026)
- 12.6.4 Enecta. Psychoactive Substances Product Portfolio
- 12.6.5 Enecta. Recent Developments
- 12.7 GD Pharma
- 12.7.1 GD Pharma Company Information
- 12.7.2 GD Pharma Business Overview
- 12.7.3 GD Pharma Revenue in Psychoactive Substances Business (2021-2026)
- 12.7.4 GD Pharma Psychoactive Substances Product Portfolio
- 12.7.5 GD Pharma Recent Developments
- 12.8 GW Pharmaceuticals PLC.
- 12.8.1 GW Pharmaceuticals PLC. Company Information
- 12.8.2 GW Pharmaceuticals PLC. Business Overview
- 12.8.3 GW Pharmaceuticals PLC. Revenue in Psychoactive Substances Business (2021-2026)
- 12.8.4 GW Pharmaceuticals PLC. Psychoactive Substances Product Portfolio
- 12.8.5 GW Pharmaceuticals PLC. Recent Developments
- 12.9 MedReleaf Australia
- 12.9.1 MedReleaf Australia Company Information
- 12.9.2 MedReleaf Australia Business Overview
- 12.9.3 MedReleaf Australia Revenue in Psychoactive Substances Business (2021-2026)
- 12.9.4 MedReleaf Australia Psychoactive Substances Product Portfolio
- 12.9.5 MedReleaf Australia Recent Developments
- 12.10 Teewinot Life Sciences
- 12.10.1 Teewinot Life Sciences Company Information
- 12.10.2 Teewinot Life Sciences Business Overview
- 12.10.3 Teewinot Life Sciences Revenue in Psychoactive Substances Business (2021-2026)
- 12.10.4 Teewinot Life Sciences Psychoactive Substances Product Portfolio
- 12.10.5 Teewinot Life Sciences Recent Developments
- 12.11 Tilray
- 12.11.1 Tilray Company Information
- 12.11.2 Tilray Business Overview
- 12.11.3 Tilray Revenue in Psychoactive Substances Business (2021-2026)
- 12.11.4 Tilray Psychoactive Substances Product Portfolio
- 12.11.5 Tilray Recent Developments
- 12.12 Zynerba Pharmaceuticals
- 12.12.1 Zynerba Pharmaceuticals Company Information
- 12.12.2 Zynerba Pharmaceuticals Business Overview
- 12.12.3 Zynerba Pharmaceuticals Revenue in Psychoactive Substances Business (2021-2026)
- 12.12.4 Zynerba Pharmaceuticals Psychoactive Substances Product Portfolio
- 12.12.5 Zynerba Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst